CytoDyn Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYDY research report →
About the company
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor.
- CEO
- Jacob Lalezari
- IPO
- 2006
- Employees
- 9
- HQ
- Vancouver, WA, US
Price Chart
- Market Cap
- $328.74M
- P/E
- -7.50
- P/S
- -55.57
- P/B
- -2.93
- EV/EBITDA
- -8.95
- Div Yield
- 0.00%
- Gross Margin
- 0.29%
- Op Margin
- 355.63%
- Net Margin
- 655.73%
- ROE
- 36.98%
- ROIC
- 104.25%
- Revenue
- $-5,916,000 · 0.00%
- Net Income
- $3.75M · 107.51%
- EPS
- $0.00 · 103.59%
- Op Income
- $11.32M
- FCF YoY
- 20.19%
- 52W High
- $0.40
- 52W Low
- $0.21
- 50D MA
- $0.30
- 200D MA
- $0.28
- Beta
- 1.12
- Avg Volume
- 2.15M
Get TickerSpark's AI analysis on CYDY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 20, 26 | Urbach Tanya Durkee | other | 574,385 |
| Mar 20, 26 | SIMES STEPHEN M | other | 574,385 |
| Mar 20, 26 | Ndhlovu Lishomwa C | other | 574,385 |
| Mar 20, 26 | Lalezari Jacob P | other | 4,874,691 |
| Mar 20, 26 | Hoffman Robert E. | other | 4,874,691 |
| Mar 20, 26 | Dunlap Ryan | other | 574,385 |
| Mar 20, 26 | Brunke Karen J | other | 574,385 |
| Mar 20, 26 | Blok Tyler | other | 3,249,794 |
| May 15, 25 | Hoffman Robert E. | other | 1,000,000 |
| May 15, 25 | Hoffman Robert E. | other | 0 |
Our CYDY coverage
Recent articles, reports, and earnings notes.
No research on CYDY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYDY report →Similar companies
Peers in the same neighborhood.